The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in San Francisco late last month. They were also published in the Journal of ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ...

周二，Stifel分析师维持对Supernus Pharmaceuticals (NASDAQ: SUPN )股票的持有评级，目标价保持在38.00美元。根据InvestingPro数据，该公司目前交易价格接近52周高点，过去六个月涨幅达30%，且保持"优秀"的财务健康评分。分析师特别指出，公司最近获得FDA批准的帕金森病 (PD)治疗用阿扑吗啡泵ONAPGO ...

周二，TD Cowen上调了Supernus Pharmaceuticals (NASDAQ: SUPN ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...